Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00261833 · ClinicalTrials.gov registry record · Phase 4
Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency
A Phase 4 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 4
- Development phase
- 180
- Enrollment target
NCT00261833 is a Phase 4 study that has completed, run by CSL Behring. The registered enrollment target is 180 participants.
The verdict
NCT00261833, a Phase 4 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 180 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled, double-blind, multicenter phase III/IV study to compare the efficacy and safety of Zemaira® with placebo in subjects with emphysema due to alpha1-proteinase inhibitor deficiency. The effect of Zemaira® on the progression of emphysema will be assessed by the decline of lung density, measured by computed tomography (CT).
Interventions
- OTHER Placebo
- BIOLOGICAL Alpha1-proteinase inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00261833
The ClinicalTrials.gov registry entry for NCT00261833 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00261833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00261833 about?
NCT00261833 is a clinical study titled "Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency". This is a randomized, placebo-controlled, double-blind, multicenter phase III/IV study to compare the efficacy and safety of Zemaira® with placebo in subjects with emphysema due to alpha1-proteinase inhibitor deficiency. The effect of Zemaira® on the progression of emphysema will be assessed by the ...
What is the current status of trial NCT00261833?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. The study started on 2006-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00261833?
The interventions under investigation include: Placebo (OTHER), Alpha1-proteinase inhibitor (BIOLOGICAL).
Who is sponsoring clinical trial NCT00261833?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.